BCPEM
GEVA

Bain Capital Public Equity Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bain Capital Public Equity Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-266,141
Closed -$16.9M – 63
2013
Q3 		$16.9M Buy
+266,141
New +$13.1M 0.42% 40

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bain Capital Public Equity Management's GEVA Position: Q4 2013 in Review

Bain Capital Public Equity Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 266,141 shares — an estimated $16.9M sold.

Bain Capital Public Equity Management first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $16.9M in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • Bain Capital Public Equity Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 266,141 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $16.9M.
  • Bain Capital Public Equity Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • Bain Capital Public Equity Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $16.9M in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2013, filed 7 Feb 2014.